Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200-Day Moving Average – Here’s Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.37 and traded as high as $3.96. Cumberland Pharmaceuticals shares last traded at $3.92, with a volume of 93,905 shares trading hands.

Analysts Set New Price Targets

A number of analysts have issued reports on CPIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised Cumberland Pharmaceuticals to a “hold” rating in a research report on Saturday, January 10th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 2.1%

The firm’s 50 day simple moving average is $4.14 and its 200-day simple moving average is $3.37. The company has a market cap of $58.64 million, a price-to-earnings ratio of -16.33 and a beta of -0.52. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC lifted its stake in Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after buying an additional 4,200 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the period. Geode Capital Management LLC raised its position in Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals in the 2nd quarter valued at $34,000. Finally, Dimensional Fund Advisors LP boosted its stake in Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the period. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.